Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 18 citing articles:

Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
Hee Kyung Ahn, Ji‐Yeon Kim, Kyung-Hun Lee, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 3, pp. 343-354
Closed Access | Times Cited: 1
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Samitha Andrahennadi, Amer Sami, Mita Manna, et al.
Current Oncology (2021) Vol. 28, Iss. 3, pp. 1803-1822
Open Access | Times Cited: 44
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
Vincenzo Di Lauro, Giacomo Barchiesi, Federica Martorana, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100629-100629
Open Access | Times Cited: 31
Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review
Evie E. M. Kolsteren, Esther Deuning‐Smit, Alanna K. Chu, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3889-3889
Open Access | Times Cited: 27
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
Imtiaz A. Samjoo, Alexandra Hall, Connie Chen, et al.
Journal of Comparative Effectiveness Research (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 5
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts
Christoph Thomssen, Diana Lüftner, Michael Untch, et al.
Breast Care (2020) Vol. 15, Iss. 1, pp. 82-95
Open Access | Times Cited: 35
Tailoring the treatment of premenopausal patients with breast cancer
Elisabetta Munzone, Carmine Valenza
The Lancet Oncology (2025)
Closed Access
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
Zsuzsanna Kahán, Miguel Gil‐Gil, Manuel Ruíz‐Borrego, et al.
European Journal of Cancer (2021) Vol. 156, pp. 70-82
Open Access | Times Cited: 24
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
Soo Hyun Lee, Kyunghee Park, Gun Min Kim, et al.
The Breast (2022) Vol. 62, pp. 52-60
Open Access | Times Cited: 18
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
Ariadna Tibau, María Teresa Martínez, Manuel Ramos, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15, pp. 175883592211489-175883592211489
Open Access | Times Cited: 7
Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer
Eugen Ruckhäberle, Marcus Schmidt, Anja Welt, et al.
Geburtshilfe und Frauenheilkunde (2024) Vol. 84, Iss. 09, pp. 813-836
Open Access | Times Cited: 2
Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
Manfred Welslau, Andreas D. Hartkopf, Volkmar Müller, et al.
Geburtshilfe und Frauenheilkunde (2019) Vol. 79, Iss. 10, pp. 1090-1099
Open Access | Times Cited: 17
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence
Benedetta Conte, Davide Soldato, Maria Grazia Razeti, et al.
Clinical Breast Cancer (2021) Vol. 22, Iss. 1, pp. 78-87
Open Access | Times Cited: 8
De novo metastatic lobular breast carcinoma: A population-based study from SEER database
Ming-Shuai Sun, Hui-Cui Yan, Min Gao, et al.
Asian Journal of Surgery (2022) Vol. 45, Iss. 12, pp. 2608-2617
Closed Access | Times Cited: 5
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial
Guillermo Villacampa, Claudette Falato, Laia Paré, et al.
European Journal of Cancer (2022) Vol. 174, pp. 232-242
Closed Access | Times Cited: 4
Identifying drivers of first-line HR+/HER2− metastatic breast cancer treatment choices
Adam Brufsky, Martine C. Maculaitis, Lewis Kopenhafer, et al.
Future Oncology (2024) Vol. 20, Iss. 29, pp. 2165-2177
Open Access
Hormonrezeptor-positives, HER2-negatives Mammakarzinom: Moderne Therapiekonzepte bei metastasierter Erkrankung
Marcus Schmidt
Trillium Krebsmedizin (2024) Vol. 33, Iss. 2, pp. 95-101
Closed Access
Sleep Quality Analysis in Metastatic Breast Cancer Patients Receiving Cyclin-Dependent Kinase 4-6 Inhibitor
Özgecan Dülgar, Sevgi FERİK, Seval Ay, et al.
Journal of Oncological Sciences (2022) Vol. 8, Iss. 3, pp. 113-118
Open Access | Times Cited: 1
Page 1

Scroll to top